EhabLAtallahMD

Oncology • Milwaukee, WI

Hematologic Oncology

Professor, Medicine, Medical College of Wisconsin

Join to view full profile

Dr. Atallah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Atallah's full profile

Already have an account?

Office
9200 W Wisconsin Ave
Neoplastic Diseases
Milwaukee, WI 53226
Phone+1 414-805-6800

Fax+1 414-805-6805

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2003 - 2004
Cleveland Clinic Foundation/Fairview HospitalResidency, Internal Medicine, 2000 - 2003
Cairo University School of MedicineClass of 1994

Certifications & Licensure

WI State Medical License 2007 - 2025
MI State Medical License 2003 - 2008
OH State Medical License 2000 - 2003
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
Completed
Phase 1
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia Start of enrollment: 2013 Jun 01
Terminated
Phase 1
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
ACTIVE_NOT_RECRUITING
PHASE3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
COMPLETED
PHASE3
Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Start of enrollment: 2017 Jun 05
Completed
Phase 2
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2017 Jun 14
TERMINATED
PHASE2
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation Start of enrollment: 2021 Nov 11
Recruiting
Phase 2
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia Start of enrollment: 2022 Feb 02
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Sponsor-Investigator
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Start of enrollment: 2019 Nov 19
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Start of enrollment: 2022 Apr 22
RECRUITING
PHASE2
Roles: Contact
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH Start of enrollment: 2021 Feb 28
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment Start of enrollment: 2024 Oct 23
NOT_YET_RECRUITING
PHASE2
Roles: Contact, Study Chair
Join now to see all

Publications & Presentations

PubMed

Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence.
Jyotirmoy Sarker, Ehab L Atallah, Kathryn E Flynn, Aaron N Winn
Leukemia & Lymphoma. 2025-03-25
1 citations
Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Prac...
Ehab L Atallah, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon
Clinical Lymphoma, Myeloma & Leukemia. 2025-03-01
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
Sameem M Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C Michaelis, Karen-Sue Carlson
Leukemia. 2025-02-15

Abstracts/Posters

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Na¥ve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive...
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Building a National CML Registry
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISIONOctober 2017

Press Mentions

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-a Solid Tumor ProgramMarch 25th, 2025
Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-a and Iomab-ACT with Clinical Data in 2H:2025March 19th, 2025
S1712 Supports Adding Ruxolitinib to TKIs for CMLSeptember 20th, 2024
Join now to see all